SCHEMBL4873530

SCHEMBL4873530

CCCCS(=O)(=O)Oc1ccc(CC(C)NC(CC)CCCCN2CCCCCC2=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
SOAT2 O75908 2/20 0.37
SOAT1 P35610 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ENPP3 O14638 1/20 0.32
ENPP1 P22413 1/20 0.32
ENPP2 Q13822 1/20 0.32
CNR1 P21554 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870422 0.96 KMT2A (0.38) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4871334 0.93 KMT2A (0.40) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4876529 0.89 KMT2A (0.39) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4870511 0.88 SOAT2 (0.42) KMT2AMEN1SOAT2SOAT1LMNA
SCHEMBL4875855 0.87 KMT2A (0.38) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4872455 0.87 SOAT2 (0.39) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4870307 0.86 SOAT2 (0.41) KMT2AMEN1SOAT2SOAT1LMNA
SCHEMBL4872680 0.85 KMT2A (0.37) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4873152 0.85 GAA (0.40) KMT2AMEN1SOAT2SOAT1SMN1; SMN2
SCHEMBL4873603 0.84 CYP1A1 (0.38) KMT2AMEN1SOAT2SOAT1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361648-B2 Heterocyclylakylamines as muscarinic receptor antagonists ROCHE PALO ALTO LLC (US) 2008-04-22 US disclosed
US-20060287293-A1 Heterocyclylalkylamines as muscarinic receptor antagonists ROCHE PALO ALTO LLC 2006-12-21 US disclosed
US-7094778-B2 Heterocyclylalkylamines as muscarinic receptor antagonists SYNTEX (U.S.A.) LLC (US) 2006-08-22 US disclosed
EP-1289965-B1 SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-10-26 EP disclosed
US-20040087581-A1 Heterocyclylalkylamines as muscarinic receptor antagonists DVORAK CHARLES ALOIS (US) 2004-05-06 US disclosed
US-6667301-B2 Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders SYNTEX (U.S.A.) LLC 2003-12-23 US disclosed
US-20020004501-A1 Heterocyclylalkylamines as muscarinic receptor antagonists SYNTEX (U.S.A.) LLC 2002-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287293-A1 Heterocyclylalkylamines as muscarinic receptor antagonists CHRM5, CHRM2, CHRM3 KMT2A 1941/4885MEN1 1954/4885SOAT2 2253/4885
US-20020004501-A1 Heterocyclylalkylamines as muscarinic receptor antagonists CHRM5, CHRM2, CHRM1 KMT2A 2014/4885MEN1 1892/4885SOAT2 2093/4885
US-20040087581-A1 Heterocyclylalkylamines as muscarinic receptor antagonists CHRM5, CHRM2, CHRM1 KMT2A 2014/4885MEN1 1892/4885SOAT2 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.